GoodGirlRx Review

Our assessment

GoodGirlRx prices nine separate products on one page: compounded semaglutide across four plan lengths, a microdose lane, an oral dissolving tablet, compounded tirzepatide, a tirzepatide microdose, and three brand-name products including a once-daily oral tablet. Very few sellers put that many priced lanes in one place. It also carries an FDA warning letter addressed to its chief executive by name, and its one fifty-state sentence is about where its providers are licensed rather than where you can buy.

Nine prices, one page

The plan block prices four commitment lengths for compounded semaglutide, each with its per-month figure. A footnote states plainly that the figure shown is the average monthly cost on a multi-month plan and that all plans are paid upfront. That footnote is what makes the low figure honest: it is a twelve-month average, not a first-month teaser, and the page says so.

Below it, a catalog rail prices a semaglutide microdose, an oral dissolving tablet, compounded tirzepatide, a tirzepatide microdose, brand-name Ozempic, brand-name Wegovy and the brand-name once-daily oral tablet. One hundred and eighteen of the four hundred and twenty sellers here offer a brand route of some kind and sixty-two of the four hundred and twenty publish a brand figure. Fifty-one of the four hundred and twenty price an oral route. This seller does both, on the same page as its compounded lanes.

One caution. A comparison block lower on the page prints a tirzepatide figure that matches the semaglutide plan floor rather than any tirzepatide product the page actually sells. Read it as marketing, not as a price you can buy.

The fifty-state sentence that is not a service area

A three-column care panel prints the words fifty states beside licensed care. The sentence underneath says the providers and compounding pharmacies are United States state-licensed. That tells you where the licenses sit, not where the service is sold, and it is the difference between a coverage claim and a compliance claim.

So there is no state list for this seller. Two hundred and eighty-six of the four hundred and twenty sellers here publish no service area at all, and a licensing sentence does not lift a seller out of that group.

The warning letter

FDA wrote to this company in February 2026, having reviewed the website in December 2025, and found its claims about compounded semaglutide and tirzepatide false or misleading under the misbranding provisions of the Act. The letter is addressed to the chief executive by name, and that is the same public figure whose name and title appear on the priced page.

Eighty of the four hundred and twenty sellers here carry a warning letter. It is disclosed here and it moves nothing. The letter turns up under the entity name and the brand name; a search keyed to this seller's domain returns nothing.